L1 Capital Pty Ltd Buys 5,000,000 Shares of Anteris Technologies Global (NASDAQ:AVR) Stock

Anteris Technologies Global Corp. (NASDAQ:AVR) major shareholder L1 Capital Pty Ltd bought 5,000,000 shares of Anteris Technologies Global stock in a transaction dated Thursday, January 22nd. The stock was acquired at an average price of $5.75 per share, with a total value of $28,750,000.00. Following the completion of the transaction, the insider directly owned 13,219,814 shares of the company’s stock, valued at approximately $76,013,930.50. The trade was a 60.83% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Anteris Technologies Global Trading Up 2.2%

AVR stock traded up $0.12 during midday trading on Monday, hitting $5.61. 692,120 shares of the company’s stock were exchanged, compared to its average volume of 2,132,993. The stock has a market capitalization of $231.13 million, a PE ratio of -3.10 and a beta of 1.29. Anteris Technologies Global Corp. has a 1-year low of $2.34 and a 1-year high of $8.79. The business has a 50-day simple moving average of $5.25 and a two-hundred day simple moving average of $4.61. The company has a current ratio of 0.84, a quick ratio of 0.80 and a debt-to-equity ratio of 0.01.

Anteris Technologies Global (NASDAQ:AVR) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.05). The business had revenue of $0.43 million during the quarter, compared to analysts’ expectations of $0.74 million. Anteris Technologies Global had a negative net margin of 3,944.93% and a negative return on equity of 252.71%. On average, sell-side analysts predict that Anteris Technologies Global Corp. will post -2.66 EPS for the current fiscal year.

Hedge Funds Weigh In On Anteris Technologies Global

Hedge funds and other institutional investors have recently bought and sold shares of the company. Marex Group plc purchased a new stake in shares of Anteris Technologies Global during the 2nd quarter worth about $641,000. Bank of America Corp DE boosted its stake in shares of Anteris Technologies Global by 35.7% in the third quarter. Bank of America Corp DE now owns 10,631 shares of the company’s stock valued at $48,000 after purchasing an additional 2,798 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Anteris Technologies Global by 34.4% during the third quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,780 shares of the company’s stock valued at $71,000 after acquiring an additional 4,036 shares in the last quarter. L1 Capital Pty Ltd increased its holdings in Anteris Technologies Global by 143.2% during the 3rd quarter. L1 Capital Pty Ltd now owns 6,838,136 shares of the company’s stock worth $30,772,000 after purchasing an additional 4,026,136 shares during the last quarter. Finally, Nantahala Capital Management LLC grew its holdings in Anteris Technologies Global by 13.3% during the 3rd quarter. Nantahala Capital Management LLC now owns 1,918,666 shares of the company’s stock worth $8,634,000 after acquiring an additional 225,000 shares in the last quarter.

Analyst Ratings Changes

Several analysts have recently weighed in on AVR shares. Lake Street Capital reaffirmed a “buy” rating and issued a $15.00 target price on shares of Anteris Technologies Global in a report on Friday, January 23rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Anteris Technologies Global in a report on Monday, December 29th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $15.00.

Anteris Technologies Global Company Profile

Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.